Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates

Core Viewpoint - Harrow (HROW) reported a quarterly loss of $0.38 per share, significantly missing the Zacks Consensus Estimate of $0.02, representing an earnings surprise of -2,000% [1] - The company's revenues for the quarter were $47.83 million, falling short of the Zacks Consensus Estimate by 19.88%, but showing an increase from $34.59 million year-over-year [2] Financial Performance - Harrow's loss per share increased from $0.28 a year ago to $0.38 this quarter, indicating a decline in financial performance [1] - The company has surpassed consensus EPS estimates two times over the last four quarters, but missed revenue estimates in the latest quarter [2] Stock Performance - Harrow shares have declined approximately 26.7% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current Zacks Rank for Harrow is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $68.63 million, and for the current fiscal year, it is $0.47 on revenues of $286.4 million [7] - The trend of estimate revisions for Harrow is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Harrow belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]